Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease
- 4 November 2006
- journal article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 51 (12) , 2165-2169
- https://doi.org/10.1007/s10620-006-9444-2
Abstract
Recent studies have shown a low adherence rate to maintenance treatment in patients with inflammatory bowel disease (IBD). We sought to assess the medication-taking behavior in a cohort of patients with IBD. We prospectively included IBD patients from the outpatient clinic who agreed to answer a questionnaire about prescribed treatment and adherence. Physicians registered clinical data including prescribed medications. Two hundred fourteen patients (115 Crohn's disease/99 ulcerative colitis) were included. The most prescribed medications were oral mesalazine (56.5%) and immunomodulators (41.1%). Forty-three percent of patients admitted to occasionally forgetting to take their medication but only 7.5% of them did it voluntary. Oral mesalazine and azathioprine were the drugs with the poorest compliance, with nonadherence rates of 45% and 25% of the total prescribed doses, respectively. The only factor associated with a better adherence was a more complicated course of the disease—steroid dependency, steroid refractoriness, need for infliximab treatment, hospitalization, or surgery (P=.02). Twenty percent of patients admitted to self-medicating. An important proportion of patients with IBD admit to forget some doses of the prescribed medication in the setting of a specialized unit of a referral centre.Keywords
This publication has 20 references indexed in Scilit:
- Systematic review: adherence issues in the treatment of ulcerative colitisAlimentary Pharmacology & Therapeutics, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitisClinical Gastroenterology and Hepatology, 2003
- A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitisClinical Gastroenterology and Hepatology, 2003
- Psychiatric Predictors of Noncompliance in Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 2001
- Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in LeicestershireEuropean Journal of Gastroenterology & Hepatology, 1996
- Mesalazine Suppositories versus Hydrocortisone Foam in Patients with Distal Ulcerative Colitis:A Comparison of the Efficacy and Practicality of Two Topical Treatment RegimensScandinavian Journal of Gastroenterology, 1995
- Why do patients with ulcerative colitis relapse?Gut, 1990
- Extent of Colonic Visualization with the Fiberoptic SigmoidoscopeJournal of Clinical Gastroenterology, 1982
- Compliance to Therapy in Patients on a Maintenance Dose of SulfasalazineJournal of Clinical Gastroenterology, 1982